Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Neurogene has a “Moderate Buy” consensus rating among six analysts: four rate it Buy, one Strong Buy, and one Sell. The average 12-month price target is $83.67, well above the stock’s $36.24 opening price.
• Recent analyst targets were mixed, with Canaccord cutting its target to $166, Guggenheim raising its target to $81, and HC Wainwright reducing its target to $65 while maintaining a Buy rating.
• Neurogene reported a quarterly loss of $1.53 per share, missing the $1.42 consensus estimate; analysts expect a full-year loss of $5.62 per share. The clinical-stage biotech is developing AAV-based gene therapies for rare neurological diseases.

Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $83.6667.

A number of equities research analysts recently commented on NGNE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Neurogene in a research report on Friday, July 17th. Canaccord Genuity Group cut their price target on shares of Neurogene from $180.00 to $166.00 and set a "buy" rating on the stock in a report on Wednesday, August 12th. Guggenheim upped their price target on Neurogene from $69.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. UBS Group set a $70.00 price objective on Neurogene in a report on Wednesday, June 3rd. Finally, HC Wainwright lowered their price objective on Neurogene from $70.00 to $65.00 and set a "buy" rating for the company in a research report on Wednesday, August 12th.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the sale, the chief financial officer directly owned 84,040 shares in the company, valued at approximately $3,036,365.20. This trade represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 9,600 shares of company stock worth $339,932. Corporate insiders own 11.68% of the company's stock.

Institutional Investors Weigh In On Neurogene

A number of large investors have recently modified their holdings of the business. State of Wyoming acquired a new position in shares of Neurogene during the second quarter valued at about $31,000. Legal & General Group Plc purchased a new position in shares of Neurogene in the 2nd quarter valued at approximately $35,000. BNP Paribas Financial Markets boosted its stake in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company's stock worth $36,000 after purchasing an additional 978 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Neurogene in the 4th quarter worth approximately $66,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company's stock.

Neurogene Stock Performance

Shares of Neurogene stock opened at $36.24 on Tuesday. The company has a market capitalization of $725.16 million, a PE ratio of -7.20 and a beta of 1.70. The company has a 50-day simple moving average of $35.89 and a two-hundred day simple moving average of $28.51. Neurogene has a one year low of $15.93 and a one year high of $43.66.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.42) by ($0.11). On average, equities analysts predict that Neurogene will post -5.62 earnings per share for the current fiscal year.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source